登录 | 注册    关注公众号  
微信公众号
搜索
 > 【EGFRvIII】

EGFRvIII信息

英文名称:Epidermal growth factor receptor variant III
中文名称:表皮生长因子受体变体III
靶点别称
上市药物数量:0
临床药物数量:13
最高研发阶段:临床二期

EGFRvIII产品列表

ACRO质量管理体系
 
评论(3)
EGI-HP2E3|PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation)
  1. 151XXXXXXX5
  2. 1人赞
  3. 购买蛋白是为了做biacore实验,实验发现蛋白的亲和力很好,做出来的结果也很符合理论,实验非常成功,蛋白非常好?
  4. 2021-12-06
EGI-H52H4|Human EGFRvIII Protein, His Tag (MALS verified)
  1. 177XXXXXXX7
  2. 0人赞
  3. 本次购买蛋白为 Human-EGFRvIII蛋白,用于foertebio octet 亲和力实验,实验结果loading信号好,结合也很好。
  4. >
  5. 2022-08-01
EGI-H52H4|Human EGFRvIII Protein, His Tag (MALS verified)
  1. 166XXXXXXX7
  2. 0人赞
  3. 人源EGFRvIII抗原与抗体亲和力很强
  4. >
  5. 2022-10-17
 

EGFRvIII分子别名

EGFRvIII

EGFRvIII分子背景

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

EGFRvIII临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Anti-EGFRvIII-CAR EGFRvIII CAR; Anti-EGFRvIII-CAR 临床二期 美国国立癌症研究所 胶质母细胞瘤, 脑癌, 神经胶质肉瘤, 胶质瘤 详情
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) CPGJ-602; 602; CPGJ602; CPGJ 602 临床二期 三生国健药业(上海)股份有限公司 结直肠癌 详情
WSD-0922 WSD-0922; WSD0922 临床一期 威尚(上海)生物医药有限公司 胶质母细胞瘤, 肿瘤, 星形细胞瘤, 非小细胞肺癌 详情
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 临床一期 宾夕法尼亚大学, 诺华制药 胶质母细胞瘤 详情
EGFRvIII-CAR 临床一期 杜克大学医学中心 胶质母细胞瘤 详情
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) 临床一期 California Institute For Regenerative Medicine, 美国国立癌症研究所 胶质母细胞瘤 详情
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) DCTY0801; DCTY-0801 临床一期 北京鼎成肽源生物技术有限公司 胶质母细胞瘤 详情
SNC-109 SNC109; SNC-109 临床一期 上海先博生物科技有限公司 胶质母细胞瘤 详情
RO-7428731 RO-7428731; RG-6156 临床一期 罗氏 胶质母细胞瘤 详情
EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) 临床一期 Chembrain Ltd 胶质母细胞瘤, 胶质瘤 详情
hEGFRvIII-CD3 Bi-scFv 临床一期 杜克大学 胶质母细胞瘤, 胶质瘤 详情
GNC-039 GNC-039 临床一期 实体瘤, 血液肿瘤, 胶质瘤, 转移癌 详情
Etevritamab AMG-596 临床一期 安进 胶质母细胞瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定